Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Schuurman, R' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 44 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Stuart, JWTC; Wensing, AMJ; Kovacs, C; Righart, M; de Jong, D; Kaye, S; Schuurman, R; Visser, CJT; Boucher, CAB
      Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    2. Vandamme, AM; Houyez, F; Banhegyi, D; Clotet, B; De Schrijver, G; De Smet, KAL; Hall, WW; Harrigan, R; Hellmann, N; Hertogs, K; Holtzer, C; Larder, B; Pillay, D; Race, E; Schmit, JC; Schuurman, R; Shulse, E; Sonnerborg, A; Miller, V
      Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up

      ANTIVIRAL THERAPY
    3. Miller, V; Vandamme, AM; Loveday, C; Staszewski, S; Lundgren, J; Youle, M; Ait-Khaled, M; Boucher, C; Brun-Vezinet, F; Dedes, N; Giaquinto, C; Hertogs, K; Houyez, F; Perrin, L; Pillay, D; Schmit, JC; Schuurman, R; Lange, J; Banhegyi, D; Biondi, G; Broekhuizen, A; Bush-Donovan, C; Camacho, R; Carlier, H; Clavel, F; Clotet, B; Clumeck, N; Colebunders, R; De Clerq, K; De Jaegher, JJ; De Schrijver, G; De Smet, K; Hall, W; Harrigan, R; Hatzakis, A; Hellmann, N; Hoetelmans, R; Holtzer, C; Katlama, C; Larder, D; Loriaux, E; McCreedy, B; Mulcahy, F; Opravil, M; Phillips, A; Ruiz, N; Shulse, E; Sonnerborg, A; Soriano, V; Steel, H; Vella, S; Williams, A
      Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting

      AIDS
    4. Caliendo, AM; Schuurman, R; Yen-Lieberman, B; Spector, SA; Andersen, J; Manjiry, R; Crumpacker, C; Lurain, NS; Erice, A
      Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma

      JOURNAL OF CLINICAL MICROBIOLOGY
    5. van Elden, LJR; Nijhuis, M; Schipper, P; Schuurman, R; van Loon, AM
      Simultaneous detection of influenza viruses A and B using real-time quantitative PCR

      JOURNAL OF CLINICAL MICROBIOLOGY
    6. Muyldermans, G; Debaisieux, L; Fransen, K; Marissens, D; Miller, K; Vaira, D; Vandamme, AM; Vandenbroucke, AT; Verhofstede, C; Schuurman, R; Zissis, G; Lauwers, S
      Blinded, multicenter quality control study for the quantification of humanimmunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories

      CLINICAL MICROBIOLOGY AND INFECTION
    7. Hugen, PWH; Burger, DM; Brinkman, K; ter Hofstede, HJM; Schuurman, R; Koopmans, PP; Hekster, YA
      Carbamazepine-indinavir interaction causes antiretroviral therapy failure

      ANNALS OF PHARMACOTHERAPY
    8. Fischer, C; Sarti, G; Casnati, A; Carrettoni, B; Manet, I; Schuurman, R; Guardigli, M; Sabbatini, N; Ungaro, R
      2,2 '-bipyridine lariat calixcrowns: A new class of encapsulating ligands forming highly luminescent Eu3+ and Tb3+ complexes

      CHEMISTRY-A EUROPEAN JOURNAL
    9. Back, NKT; van Wijk, A; Remmerswaal, D; van Monfort, M; Nijhuis, M; Schuurman, R; Boucher, CAB
      In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

      AIDS
    10. Van Vaerenbergh, K; Van Laethem, K; Albert, J; Boucher, CAB; Clotet, B; Floridia, M; Gerstoft, J; Hejdeman, B; Nielsen, C; Pannecouque, C; Perrin, L; Pirillo, MF; Ruiz, L; Schmit, JC; Schneider, F; Schoolmeester, A; Schuurman, R; Stellbrink, HJ; Stuyver, L; Van Lunzen, J; Van Remoortel, B; Van Wijngaerden, E; Vella, S; Witvrouw, M; Yerly, S; De Clercq, E; Desmyter, J; Vandamme, AM
      Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    11. Jongerius, JM; Bovenhorst, M; van der Poel, CL; van Hilten, JA; Kroes, ACM; van der Does, JA; van Leeuwen, EF; Schuurman, R
      Evaluation of automated nucleic acid extraction devices for application inHCVNAT

      TRANSFUSION
    12. Frost, SDW; Nijhuis, M; Schuurman, R; Boucher, CAB; Brown, AJL
      Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

      JOURNAL OF VIROLOGY
    13. Van Laethem, K; Van Vaerenbergh, K; Schmit, JC; Sprecher, S; Hermans, P; De Vroey, V; Schuurman, R; Harrer, T; Witvrouw, M; Van Wijngaerden, E; Stuyver, L; Van Ranst, M; Desmyter, J; De Clercq, E; Vandamme, AM
      Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    14. Kamp, W; Schokker, J; Cambridge, E; De Jong, S; Schuurman, R; De Groot, T; Boucher, CAB
      Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results ofa Phase I/II study

      ANTIVIRAL THERAPY
    15. Stuart, JWTC; Schuurman, R; Burger, DM; Koopmans, PP; Sprengers, HG; Juttmann, JR; Richter, C; Meenhorst, PL; Hoetelmans, RMW; Kroon, FP; Bravenboer, B; Hamann, D; Boucher, CAB; Borleffs, JCC
      Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)

      AIDS
    16. Nijhuis, M; Schuurman, R; de Jong, D; Erickson, J; Gustchina, E; Albert, J; Schipper, P; Gulnik, S; Boucher, CAB
      Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

      AIDS
    17. Casado, JL; Arrizabalaga, J; Montes, M; Marti-Belda, P; Tural, C; Pinilla, J; Gutierrez, C; Portu, J; Schuurman, R; Aguirrebengoa, K
      Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy

      AIDS
    18. Keulen, W; van Wijk, A; Schuurman, R; Berkhout, B; Boucher, CAB
      Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential

      AIDS
    19. Aboulker, JP; Babiker, AG; Brun-Vezinet, F; Darbyshire, JH; Flandre, P; Gazzard, B; Nunn, AJ; Goodall, R; Aber, V; Bragman, K; Breckenridge, AM; Carbon, C; Charreau, I; Chene, G; Collis, P; Cooper, D; Dormont, J; Fiddian, P; Flepp, M; Goebel, FD; Hooker, M; Lange, J; Luthy, R; Peto, TEA; Reiss, P; Seligmann, M; Stone, AB; Thomis, J; Vella, S; Walckenaer, G; Warrell, D; Weller, IVD; Wilber, R; Yeni, P; Yeo, J; Withnall, R; Goudsmit, J; Huraux, JM; van der Noorda, J; Weiss, R; Boucher, C; Schuurman, R; Descamps, D; Jeffries, D; Tedder, R; Weber, J; Krzyanowski, C; Weverling, G
      HIV-1 RNA response to antiretroviral treatment in 1280 participants in theDelta Trial: an extended virology study

      AIDS
    20. Schuurman, R; Demeter, L; Reichelderfer, P; Tijnagel, J; de Groot, T; Boucher, C
      Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase

      JOURNAL OF CLINICAL MICROBIOLOGY
    21. BRUISTEN SM; REISS P; LOELIGER AE; VANSWIETEN P; SCHUURMAN R; BOUCHER CAB; WEVERLING GJ; HUISMAN JG
      CELLULAR PROVIRAL HIV TYPE-1 DNA LOAD PERSISTS AFTER LONG-TERM RT-INHIBITOR THERAPY IN HIV TYPE-1 INFECTED PERSONS

      AIDS research and human retroviruses
    22. WOUT ABVT; RAN LJ; NIJHUIS M; TIJNAGEL JMGH; DEGROOT T; VANLEEUWEN R; BOUCHER CAB; SCHUITEMAKER H; SCHUURMAN R
      EFFICIENT INHIBITION OF BOTH SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING WILD-TYPE HIV-1 BY LAMIVUDINE IN-VIVO

      AIDS
    23. NIJHUIS M; BOUCHER CAB; SCHIPPER P; LEITNER T; SCHUURMAN R; ALBERT J
      STOCHASTIC-PROCESSES STRONGLY INFLUENCE HIV-1 EVOLUTION DURING SUBOPTIMAL PROTEASE-INHIBITOR THERAPY

      Proceedings of the National Academy of Sciences of the United Statesof America
    24. NIJHUIS M; SCHUURMAN R; BOUCHER CAB
      HOMOLOGOUS RECOMBINATION FOR RAPID PHENOTYPING OF HIV

      Current opinion in infectious diseases
    25. SCHUURMAN R
      STATE-OF-THE-ART OF GENOTYPIC HIV-1 DRUG-RESISTANCE

      Current opinion in infectious diseases
    26. BEENTIKTAK AMM; DEHAAS CJC; DEGRAAF L; BOUCHER CAB; VERHOEF J; BORLEFFS JCC; NOTTET HSLM; SCHUURMAN R
      IN-VITRO SELECTION OF HIV-1 VARIANTS RESISTANT TO NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS IN MONOCYTE-DERIVED MACROPHAGES

      Journal of antimicrobial chemotherapy
    27. BRUNVEZINET F; BOUCHER C; LOVEDAY C; DESCAMPS D; FAUVEAU V; IZOPET J; JEFFRIES D; KAYE S; KRZYANOWSKI C; NUNN A; SCHUURMAN R; SEIGNEURIN JM; TAMALET C; TEDDER R; WEBER J; WEVERLING GJ; ABER V; ABOULKER JP; BABIKER AG; BRAGMAN K; BRECKENRIDGE AM; CARBON C; CHARREAU I; CHENE G; COLLIS P; COOPER D; DARBYSHIRE JH; DORMONT J; FIDDIAN P; FLEPP M; GAZZARD B; GOEBEL FD; HOOKER M; LANGE J; LUTHY R; PETO TEA; REISS P; SELIGMANN M; STONE AB; THOMIS J; VELLA S; WALCKENAER G; WARRELL D; WELLER IVD; WILBER R; YENI P; YEO J; WITHNALL R; BABIKER A; BLOCH J; POUCHER C; DARBYSHIRE J; GOUDSMIT J; HURAUX JM; VANDERNOORDAA J; WEISS R; WEVERLING G
      HIV-1 VIRAL LOAD, PHENOTYPE, AND RESISTANCE IN A SUBSET OF DRUG-NAIVEPARTICIPANTS FROM THE DELTA-TRIAL

      Lancet
    28. KEULEN W; NIJHUIS M; SCHUURMAN R; BERKHOUT B; BOUCHER C
      REVERSE-TRANSCRIPTASE FIDELITY AND HIV-1 VARIATION

      Science
    29. STILIANAKIS NI; BOUCHER CAB; DEJONG MD; VANLEEUWEN R; SCHUURMAN R; DEBOER RJ
      CLINICAL-DATA SETS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE TRANSCRIPTASE-RESISTANT MUTANTS EXPLAINED BY A MATHEMATICAL-MODEL

      Journal of virology
    30. NIJHUIS M; SCHUURMAN R; DEJONG D; VANLEEUWEN R; LANGE J; DANNER S; KEULEN W; DEGROOT T; BOUCHER CAB
      LAMIVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS (184V) REQUIRE MULTIPLE AMINO-ACID CHANGES TO BECOME CO-RESISTANT TO ZIDOVUDINE IN-VIVO

      The Journal of infectious diseases
    31. DERONDE A; SCHUURMAN R; GOUDSMIT J; VANDENHOEK A; BOUCHER C
      FIRST CASE OF NEW INFECTION WITH ZIDOVUDINE-RESISTANT HIV-1 AMONG PROSPECTIVELY STUDIED INTRAVENOUS-DRUG-USERS AND HOMOSEXUAL MEN IN AMSTERDAM, THE NETHERLANDS

      AIDS
    32. SCHUURMAN R; DESCAMPS D; WEVERLING GJ; KAYE S; TIJNAGEL J; WILLIAMS I; VANLEEUWEN R; TEDDER R; BOUCHER CAB; BRUNVEZINET F; LOVEDAY C
      MULTICENTER COMPARISON OF 3 COMMERCIAL METHODS FOR QUANTIFICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA

      Journal of clinical microbiology
    33. DEJONG MD; VEENSTRA J; STILIANAKIS NI; SCHUURMAN R; LANGE JMA; DEBOER RJ; BOUCHER CAB
      HOST-PARASITE DYNAMICS AND OUTGROWTH OF VIRUS CONTAINING A SINGLE K70R AMINO-ACID CHANGE IN REVERSE-TRANSCRIPTASE ARE RESPONSIBLE FOR THE LOSS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA LOAD SUPPRESSION BY ZIDOVUDINE

      Proceedings of the National Academy of Sciences of the United Statesof America
    34. DEJONG MD; VEENSTRA J; STILIANAKIS N; SCHUURMAN R; DEBOER RJ; LANGE JMA; BOUCHER CAB
      RETURN TO BASE-LINE VALUES OF HIV-1 RNA LOAD DURING ZIDOVUDINE TREATMENT IS ASSOCIATED WITH THE EMERGENCE OF K70R MUTANT VIRUS

      Journal of acquired immune deficiency syndromes and human retrovirology
    35. VANTWOUT AB; DEJONG MD; KOOTSTRA NA; SCHUURMAN R; COUTINHO R; BOUCHER CAB; SCHUITEMAKER H
      PREFERENTIAL INHIBITION OF NON-SYNCYTIUM-INDUCING HIV-1 VARIANTS BY ZIDOVUDINE

      Journal of acquired immune deficiency syndromes and human retrovirology
    36. SCHUURMAN R; VANLEEUWEN R; NIJHUIS M; KWOK S; DEJONG D; BOUCHER C
      TURNOVER OF SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING HIV-1 IN PATIENTS TREATED WITH 3TC

      Journal of acquired immune deficiency syndromes and human retrovirology
    37. NIJHUIS M; DEJONG D; VANLEEUWEN R; DEGROOT T; KEULEN W; SCHUURMAN R; BOUCHER C
      THE RISE IN HIV-1 RNA LOAD DURING 3TC AZT COMBINATION THERAPY IS ASSOCIATED WITH THE SELECTION OF VIRUSES RESISTANT TO BOTH 3TC AND AZT/

      Journal of acquired immune deficiency syndromes and human retrovirology
    38. DEJONG MD; SCHUURMAN R; LANGE JMA; BOUCHER CAB
      RAPID SELECTIVE OUTGROWTH OF A MINOR PREEXISTING DRUG-RESISTANT HIV-1SUBPOPULATION DURING SUBSEQUENT NEVIRAPINE TREATMENT

      Journal of acquired immune deficiency syndromes and human retrovirology
    39. BACK N; KEULEN W; NIJHUIS M; VANBOMMEL T; DEJONG D; DEJONG M; SCHUURMAN R; BOUCHER C
      A CONVENIENT APPROACH TO DETERMINING THE DRUG SUSCEPTIBILITY FROM SERUM HIV-1 RNA

      Journal of acquired immune deficiency syndromes and human retrovirology
    40. VEENSTRA J; SCHUURMAN R; CORNELISSEN M; VANTWOUT AB; BOUCHER CAB; SCHUITEMAKER H; GOUDSMIT J; COUTINHO RA
      TRANSMISSION OF ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS FOLLOWING DELIBERATE INJECTION OF BLOOD FROM A PATIENT WITH AIDS - CHARACTERISTICS AND NATURAL-HISTORY OF THE VIRUS

      Clinical infectious diseases
    41. NIJHUIS M; BOUCHER CAB; SCHUURMAN R
      SENSITIVE PROCEDURE FOR THE AMPLIFICATION OF HIV-1 RNA USING A COMBINED REVERSE-TRANSCRIPTION AND AMPLIFICATION REACTION

      BioTechniques
    42. SCHUURMAN R; NIJHUIS M; VANLEEUWEN R; SCHIPPER P; DEJONG D; COLLIS P; DANNER SA; MULDER J; LOVEDAY C; CHRISTOPHERSON C; KWOK S; SNINSKY J; BOUCHER CAB
      RAPID CHANGES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA LOAD AND APPEARANCE OF DRUG-RESISTANT VIRUS POPULATIONS IN PERSONS TREATED WITH LAMIVUDINE (3TC)

      The Journal of infectious diseases
    43. FRISSEN PHJ; VANDERENDE ME; TENNAPEL CHH; WEIGEL HM; SCHREIJ GS; KAUFFMANN RH; KOOPMANS PP; HOEPELMAN AIM; DEBOER JB; WEVERLING GJ; HAVERKAMP G; DOWD P; MIEDEMA F; SCHUURMAN R; BOUCHER CAB; LANGE JMA
      ZIDOVUDINE AND INTERFERON-ALPHA, COMBINATION THERAPY VERSUS ZIDOVUDINE MONOTHERAPY IN SUBJECTS WITH SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION

      The Journal of infectious diseases
    44. BOUCHER CAB; CAMMACK N; SCHIPPER P; SCHUURMAN R; ROUSE P; WAINBERG MA; CAMERON JM
      HIGH-LEVEL RESISTANCE TO (-) ENANTIOMERIC 2'-DEOXY-3'-THIACYTIDINE IN-VITRO IS DUE TO ONE AMINO-ACID SUBSTITUTION IN THE CATALYTIC SITE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE

      Antimicrobial agents and chemotherapy


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/06/20 alle ore 20:33:35